血清肿瘤标记物与卵巢癌诊断和监控治疗的相关性研究

Correlafivity study on serum tumor markers and ovarian cancer diagnosis and monitoring treatment

目的 探讨血清肿瘤标记物糖类抗原CA125、CA724、环氧化酶（COX-1）和人附睾蛋白4（HE4）联合动态检测在卵巢癌早期诊断和监控治疗、复发中的临床应用价值。方法选取82例卵巢癌患者（观察组）、79例卵巢良性病变患者（对照组）为研究对象，均经术后病理确诊。所有患者术前、术后均有血清肿瘤标记物CA125、CA724、COX—1、HE4检查资料，其中CA125、CA724、COX-1采用电化学发光法检测，HE4采用酶联免疫（ELISA）法检测，综舍评价四种肿瘤标记物联合动态检测在卵巢癌早期诊断和监控治疗、复发中的价值。结果卵巢癌组患者血清CA125、CA724、COX-1、HE4水平明显高于卵巢良性病变组（P〈0．01）；卵巢癌高分期（Ⅲ、Ⅳ期）组明显高于低分期（I、II）纽（P〈0．01），卵巢癌术前、复发组与术后、无复发组血清肿瘤标记物水平差异有统计学意义（P（0．01）。CA125、CA724、COX-1、HE4诊断卵巢癌的敏感性分别为74．4％、70．7％、43．9％、69．5％，联合检测的敏感性高达96．3％，与各单项检测的敏感性比较差异有统计学意义（P〈0．01）。结论血清肿瘤标记物CA125、CA724、COX-1、HFA联合动态检测是卵巢癌早期诊断和监控治疗、复发的较好指标，有利于临床早期发现、早期干预。

Objective This paper has investigated the clinical value of combined dynamic detection of serum tumor markers of CA125, CA724, COX- 1 and HFA applied in the early diagnosis, monitoring treatment and recrudescence of ovarian cancer. Method In this study, 82 cases of ovarian cancer patients （observation group） and 79 eases of benign ovarian lesion patients （control group） were selected, which were all confirmed with postoperative pathology diagnosis. The preoperative and postoperative test data of all patients＇ serum tumor markers of CA125, CA724, COX-1 and HE4 was collected, of which the CA125, CA724, COX- 1 were detected by electrochemical 1 method, and HE4 was detected by enzyme - linked immunosorbent assay （ELISA）. The clinical value of combined dynamic detection of 4 serum tumor markers applied in the early diagnosis, monitoring treatment and recrudescence was comprehensive evaluated. Results The levels of the tumor makers CA125, CA724 COX - 1 and HE4 of Ovarian caneergroup were apparently higher than those of benign ovarian group （p 〈 0.01 ）. The high stage （ Ⅲ , Ⅳ ） of ovarian cancer group was significantly higher than thai of the low stage （ Ⅰ , Ⅱ ） （p 〈 0.01 ）. The difference of tumor makers level of preoperative, recrudescence group comparing with postoperative, no recurrence group were statistical significant （p 〈 0.01）. The diagnosis of ovarian cancer sensitivity of CA125, CA724, COX - 1 and HE4 were 74.4%, 70.7%, 43.9% and 69. 5 %. The sensitivity of combined dynamic detection can reach up to 96.3 %, which was statistical signitlcant comparing with each individual indicator. Conclusions The combined dynamic detection of CA125, CA724, COX - 1 and HFA was a good indicator of early diagnosis, moni- toring treatment and recrudescence of ovarian cancer, which was favorable for clinical early detection and early intervention.